How much funding has Volastra Therapeutics raised?

Volastra Therapeutics has raised $134.1M in total funding, most recently a Series B round.

Who are Volastra Therapeutics's investors?

Volastra Therapeutics's investors include Andreessen Horowitz, B Capital Group, Eli Lilly, Samsara BioCapital, Atlas Venture.

When was Volastra Therapeutics founded?

Volastra Therapeutics was founded in 2019.

Where is Volastra Therapeutics headquartered?

Volastra Therapeutics is headquartered in New York City, New York, United States.

What industry is Volastra Therapeutics in?

Volastra Therapeutics operates in Biotech, Healthcare.

How many employees does Volastra Therapeutics have?

Volastra Therapeutics has 11-50 employees.

Volastra Therapeutics

Volastra - Short Circuiting Cancer's Chaos

New York City, United States · Founded 2019 · $134.1M raised

Biotech

Healthcare

Headquarters: New York City, New York
Employees: 11–50
Founded: 2019
Business Model: B2B

Website: volastratx.com
Total Funding: $134.1M
Last Round: $30.1M Series BSep 2025
Rounds: 3

About

Volastra Therapeutics is a clinical-stage oncology biotech company based in New York City, pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN). Founded by Lewis Cantley, Olivier Elemento, and Samuel Bakhoum, Volastra is advancing a synthetic lethal and immune-activating pipeline including two KIF18A inhibitors currently in Phase 1 clinical trials.

Summary

Volastra Therapeutics is a Biotech company based in New York City, United States, founded in 2019. It has raised $134.1M in total across 3 rounds, most recently a $30.1M Series B round in Sep 2025. Investors include Andreessen Horowitz, B Capital Group and Eli Lilly.

X (Twitter)